Dynamic Technology Lab Private Ltd Purchases Shares of 46,326 STAAR Surgical Company $STAA

Dynamic Technology Lab Private Ltd purchased a new stake in STAAR Surgical Company (NASDAQ:STAA) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 46,326 shares of the medical instruments supplier’s stock, valued at approximately $1,070,000. Dynamic Technology Lab Private Ltd owned about 0.09% of STAAR Surgical as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Invesco Ltd. increased its position in shares of STAAR Surgical by 0.6% in the third quarter. Invesco Ltd. now owns 150,896 shares of the medical instruments supplier’s stock valued at $4,055,000 after buying an additional 956 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of STAAR Surgical by 2,605.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 1,016 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of STAAR Surgical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock valued at $518,000 after buying an additional 1,267 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of STAAR Surgical by 3.7% in the fourth quarter. Deutsche Bank AG now owns 38,586 shares of the medical instruments supplier’s stock worth $891,000 after acquiring an additional 1,382 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of STAAR Surgical by 3.6% in the third quarter. CANADA LIFE ASSURANCE Co now owns 57,625 shares of the medical instruments supplier’s stock worth $1,546,000 after acquiring an additional 1,979 shares during the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

STAAR Surgical Stock Performance

NASDAQ STAA opened at $28.37 on Friday. The stock’s fifty day moving average is $27.65 and its two-hundred day moving average is $23.23. The firm has a market capitalization of $1.41 billion, a P/E ratio of -65.98 and a beta of 1.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.31 and a current ratio of 5.12. STAAR Surgical Company has a fifty-two week low of $15.59 and a fifty-two week high of $35.87.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The company had revenue of $93.52 million for the quarter, compared to analyst estimates of $78.72 million. During the same quarter in the previous year, the company posted ($1.10) earnings per share. The firm’s revenue for the quarter was up 119.6% compared to the same quarter last year. On average, research analysts anticipate that STAAR Surgical Company will post 0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Piper Sandler lifted their price target on STAAR Surgical from $16.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Wells Fargo & Company lifted their price target on STAAR Surgical from $16.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Friday, May 15th. Mizuho lifted their price target on STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Canaccord Genuity Group lifted their price target on STAAR Surgical from $27.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Finally, Wedbush reissued an “outperform” rating and set a $40.00 price objective on shares of STAAR Surgical in a research note on Friday, May 29th. Three analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.81.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.